NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Cyxone AB (publ) ("Cyxone" or "the Company") completed a directed issue of units during the fourth quarter of 2021. One (1) unit consisted of one (1) newly issued share and one (1) warrant of series TO4. Each warrant entitles the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period, from April 29, 2021, to May 12, 2021. However not less than SEK 2.00 and not exceeding SEK 7.05 per new share. During the measurement period the volume-weighted average price of the Company's share amounted to approximately SEK 4,63, therefore, the exercise price for the warrants of series TO4 is set to SEK 3.24. The exercise period for the subscription of new shares with warrants of series TO4 will be from May 17, 2021, up to and including May 28, 2021.

If all the warrants of series TO4 are exercised, the Company will receive approximately SEK 19.5 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than May 28, 2021 or sell the warrants no later than May 21, 2021. Please observe that certain nominees may close their applications earlier than May 28, 2021.

Summarized terms for the warrants of series TO4:

Exercise period: May 17, 2021 - May 28, 2021

Issue size: 6,003,157 warrants of series TO4, which entitles to subscription of 6,003,157 shares. If all the warrants are exercised, the Company will receive approximately SEK 19.5 million before issuing costs.  

Last day of trading warrants of series TO4: May 21, 2021

Dilution etc.: If all warrants are exercised the share capital will increase with approximately SEK 453,068.70, from SEK 4,382,145.83 to SEK 4,835,214.53. If all warrants are exercised the number of shares will increase with 6,003,157 shares, from 58,063,400 shares, to 64,066,557 shares. The dilution at the exercise of all warrants amounts to approximately 9.37 percent of the number of shares and votes.

Note that the warrants that are not exercised at the latest May 28, 2021, or sold at the latest May 21, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)

Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

The application form including instructions for payment will be available at Cyxone's website, www.cyxone.com and on Mangold Fondkommission AB's website, www.mangold.se.

Advisers

Mangold Fondkommission AB is the financial adviser and Fredersen Advokatbyrå AB is the legal adviser for Cyxone regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB
Tel: +46 8 5050 1595
Email: emissioner@mangold.se

Contact

Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com.

https://news.cision.com/cyxone/r/the-exercise-price-for-the-warrants-of-series-to4-in-cyxone-ab-has-been-determined-to-sek-3-24-and-t,c3346744

https://mb.cision.com/Main/16882/3346744/1417365.pdf

• Cyxone AB